Thomas W. LeBlanc, MD, MA, MHS and Arif H. Kamal, MD, MBA, MHS
Clinical trials should assess patients’ distress and test interventions to address it, just as they assess adverse events and test novel therapeutic agents.
AMA J Ethics. 2017; 19(5):460-466. doi:
10.1001/journalofethics.2017.19.5.stas1-1705.
Hilary Daniel joins Ethics Talk to discuss her article, coauthored with Courtney Perlino and Dr Amy B. Cadwallader: “Which Drugs Should Be on the Essential Medicines List?”
Thomas W. LeBlanc, MD, MA and Amy P. Abernethy, MD, PhD
One strategy to promote adherence is the use of “care pathways,” effectively roadmaps that seek to standardize cancer treatment on the basis of some agreed-upon set of guidelines within a particular center or group of patients.
The high price of cancer drugs in the US relative to European countries with universal health care raises ethical issues of access, financial burden on patients, and unsustainability of the health care system.
AMA J Ethics. 2015; 17(8):750-753. doi:
10.1001/journalofethics.2015.17.8.nlit1-1508.
LaPrincess C. Brewer, MD, MPH and Lisa A. Cooper, MD, MPH
Stressful life experience associated with racial and ethnic discrimination can have detrimental effects on the coronary and cardiovascular health of people in historically marginalized groups.
When identifying underrepresented subgroups deserving of special recruitment efforts for research participation, social determinants of health other than race should be given more consideration.